The Importance Of RUNX3 In Preventing Gastrointestinal Diseases And Tumour Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
Stomach cancer is the second leading cause of cancer-related deaths. It is estimated that in 2010, more than 1 million people will die of stomach cancer with an increase of 19%. Studies have revealed that RUNX3 has the ability to suppress the growth of stomach cancer. However the role of RUNX3 in preventing metastasis is yet unknown. Therefore, an understanding of the factors that govern metastasis will inform the design of effective therapies to prevent mortality which is high for this disease.
I am a cell biologist/geneticist focusing on understanding tumourigenesis. Cancer is a multigenic and complicated disease, involving interactions between the tumour and normal tissue. I use the genetically tractable model organism, the vinegar fly, Drosophila, to model cancer in situ and identify novel genes that drive cancer. My 5 year career plan is to use the Drosophila system to model cooperative tumourigenesis in epithelial and brain tissues and translate this to human cancer.
Lymphangiogenesis From Development To Disease: Analysis Of SOX18 Function In The Control Of Lymphatic Remodeling
Funder
National Health and Medical Research Council
Funding Amount
$401,361.00
Summary
Cancers are lethal mainly because they spread (metastasise) to other parts of the body via blood vessels and lymphatic ducts. Pilot studies suggest that suppressing the function of a gene, SOX18, reduces tumour metastasis. We now propose to confirm these findings and study this effect in detail, with the ultimate aim of developing new therapies able to complement already existing anti-cancer treatments.
Every cell in our body has an intrinsic orientation that is controlled by a universal set of genes known as polarity genes. Loss of this orientation is a common and early feature of cancer. We have identified the gene Scribble as a gene that controls cell orientation and is essential to prevent the development of prostate cancer. We propose experiments to discover how Scribble controls prostate cancer and whether it can be used to better predict outcome for prostate cancer patients.
We have discovered that part of a collagen molecule - lamstatin- inhibits growth of lymphatic cells and their communicating networks. Excessive lymphatic growth occurs in lymphangioleiomyomatosis (LAM)- a fatal disease which affects young women- and many cancers. We have shown that lamstatin prevents growth of lymph vessels in a skin tumour in mice and we will investigate if it can prevent spread of tumours to other organs which has exciting implications for the treatment of cancer.
ADAM Metalloprotease Inhibition For Treatment Of Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$770,925.00
Summary
Colorectal cancer (CRC) causes over 4000 deaths/year, typically from developing drug resistance and spreading to other organs (metastasis). These processes involve tumour cells called cancer stem cells (CSCs), which rely on specific cell surface proteins for survival and function. We are developing antibodies against one of these type of proteins, to test in mouse models of CRC. These already show promise in targeting CSCs and inhibiting drug-resistance and metastasis in mice.
BMP4 - A Metastasis Suppressor Gene In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$454,220.00
Summary
Breast cancer is the most common cause of cancer death in western women. Whilst the primary tumour can often be eradicated successfully, in many cases, it may have already spread to other organs, including lungs, liver and bone, causing severe morbidity. Current treatments are largely palliative and new therapies that specifically prevent to spread of breast cancer are urgently required. However, little is known about the molecular pathways regulating the spread of cancer cells. We have shown th ....Breast cancer is the most common cause of cancer death in western women. Whilst the primary tumour can often be eradicated successfully, in many cases, it may have already spread to other organs, including lungs, liver and bone, causing severe morbidity. Current treatments are largely palliative and new therapies that specifically prevent to spread of breast cancer are urgently required. However, little is known about the molecular pathways regulating the spread of cancer cells. We have shown that expression of a gene called BMP4 in tumours blocks the spread of breast cancer in a mouse model. The aim of this project is to develop the application of BMP4 as a therapy for advanced breast cancer using our mouse model. We will measure the expression of BMP4 in human breast cancer and test whether treatment with purified BMP4 protein can protect mice from the spread of breast cancer. If successful, this study will offer a new therapy for women with currently incurable breast cancer.Read moreRead less
Parathyroid Hormone-related Protein (PTHrP), Common Genetic Variants In The PTHrP Gene (PTHLH), And Breast Cancer Risk And Survival
Funder
National Health and Medical Research Council
Funding Amount
$120,253.00
Summary
In a partnership between Peter MacCallum Cancer Centre, St Vincent's Hospital, and The University of Melbourne, we are investigating the role of PTHrP, a peptide integral to the growth and spread of Cancer. Initially thought to facilitate cancer spread, recent studies suggest it may actually be protective. In a new approach, we will analyse new DNA databases and patient data from around the world. We hope to extend our understanding of PTHrP, and perhaps find novel drug and therapeutic targets.
Examining The Role Of Profilin As A Regulator Of Cancer Aggressiveness
Funder
National Health and Medical Research Council
Funding Amount
$261,778.00
Summary
Cancer treatment in Australia costs ~ $2.7 billion per annum. Current mainstream treatments often cause major side effects and thus less toxic therapeutic approaches are urgently needed. Profilin has recently emerged as a promising anti-cancer target. We will investigate how cancer can be suppressed by altering the interaction between profilin and its partners (lipids, phosphoinositides, and actin). This project will provide essential groundwork for the development of novel cancer therapeutics.